<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=3190596&amp;fmt=gif">

Thyme Care closes $95M Series C to advance optimization of care, navigation

Published by on

Thyme Care announced the close of a $95 million capital raise. With $55 million in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. 

 

Click here to read the full article.
Tags:
Back to Blog

Related Articles

ThymeCare-Logo-Wordmark-OffWhite 1

Subscribe to the latest updates:
About Us
Partners
Members
Privacy
    Company
    Members
    Partners
    Legal
    © 2024 Thyme Care, Inc. All Rights Reserved. Thyme Care, Inc. and Thyme Care Medical, PLLC. (collectively "Thyme Care", "we", "us" "our") make up the Thyme Care organization. Thyme Care, Inc. provides management support services to Thyme Care Medical, PLLC and non-clinical cancer support services to its members. Thyme Care Medical, PLLC is a health care provider that offers clinical cancer support services to its patients. Thyme Care Medical, PLLC does not direct diagnosis or prescribing of medication for cancer treatment.
    © 2024 Thyme Care, Inc. All Rights Reserved. Thyme Care, Inc. and Thyme Care Medical, PLLC. (collectively "Thyme Care", "we", "us" "our") make up the Thyme Care organization. Thyme Care, Inc. provides management support services to Thyme Care Medical, PLLC and non-clinical cancer support services to its members. Thyme Care Medical, PLLC is a health care provider that offers clinical cancer support services to its patients. Thyme Care Medical, PLLC does not direct diagnosis or prescribing of medication for cancer treatment.